Literature DB >> 23635604

Mineralocorticoid receptor blockade reduced oxidative stress in renal transplant recipients: a double-blind, randomized pilot study.

Marcos Ojeda-Cervantes1, Jonatan Barrera-Chimal, Josefina Alberú, Rosalba Pérez-Villalva, Luis Eduardo Morales-Buenrostro, Norma A Bobadilla.   

Abstract

BACKGROUND: Previous experimental studies from our laboratory have demonstrated that aldosterone plays a central role in renal ischemic processes. This study was designed to evaluate the effect of mineralocorticoid receptor blockade in renal transplant recipients from living donors.
METHODS: 20 adult kidney transplant recipients from living donors were included in a double-blind, randomized, placebo-controlled clinical pilot study that compared spironolactone and placebo. Placebo or spironolactone (25 mg) was administered 1 day before and 3 days posttransplantation. Renal function and urinary kidney injury molecule-1, interleukin-18, and heat shock protein 72 as well as urinary hydrogen peroxide (H2O2) levels were quantified.
RESULTS: No significant differences were seen between the groups studied regarding age, gender, indication for kidney transplantation, residual renal function, renal replacement therapy, or warm and cold ischemia periods. In contrast, spironolactone administration significantly reduced the oxidative stress assessed by the urinary H2O2 excretion, in spite of no differences in renal function or reduction in tubular injury biomarkers.
CONCLUSIONS: The findings of this exploratory study strongly suggest that aldosterone promotes oxidative stress and that the administration of spironolactone reduces the production of urinary H2O2 as a result of lesser formation of surrogate reactive oxygen species secondary to the ischemia-reperfusion phenomenon.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23635604     DOI: 10.1159/000350539

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  10 in total

1.  New roles of aldosterone and mineralocorticoid receptors in cardiovascular disease: translational and sex-specific effects.

Authors:  Ana Paula Davel; Iris Z Jaffe; Rita C Tostes; Frederic Jaisser; Eric J Belin de Chantemèle
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-06-29       Impact factor: 4.733

2.  Randomized Controlled Trial of Mineralocorticoid Receptor Blockade in Children with Chronic Kidney Allograft Nephropathy.

Authors:  Mara Medeiros; Luis Velásquez-Jones; Ana M Hernández; Guillermo Ramón-García; Saúl Valverde; Yolanda Fuentes; Arindal Vargas; Mauricio Patiño; Rosalba Pérez-Villalva; Juan Antonio Ortega-Trejo; Jonatan Barrera-Chimal; Norma A Bobadilla
Journal:  Clin J Am Soc Nephrol       Date:  2017-05-23       Impact factor: 8.237

3.  Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial.

Authors:  Sawako Kato; Shoichi Maruyama; Hirofumi Makino; Jun Wada; Daisuke Ogawa; Takashi Uzu; Hisazumi Araki; Daisuke Koya; Keizo Kanasaki; Yutaka Oiso; Motomitsu Goto; Akira Nishiyama; Hiroyuki Kobori; Enyu Imai; Masahiko Ando; Seiichi Matsuo
Journal:  Clin Exp Nephrol       Date:  2015-03-21       Impact factor: 2.801

Review 4.  Does Mineralocorticoid Receptor Antagonism Prevent Calcineurin Inhibitor-Induced Nephrotoxicity?

Authors:  Line Aas Mortensen; Claus Bistrup; Helle Charlotte Thiesson
Journal:  Front Med (Lausanne)       Date:  2017-11-24

5.  Pirfenidone prevents acute kidney injury in the rat.

Authors:  Ixchel Lima-Posada; Francesco Fontana; Rosalba Pérez-Villalva; Nathan Berman-Parks; Norma A Bobadilla
Journal:  BMC Nephrol       Date:  2019-05-08       Impact factor: 2.388

6.  The safety and efficacy of low-dose mineralocorticoid receptor antagonists in dialysis patients: A meta-analysis.

Authors:  Yifan Zhu; Yueming Liu; Ruyi Cai; Danna Zheng; Xudong Liang; Mei Tao; Juan Jin; Yiwen Li; Qiang He
Journal:  Medicine (Baltimore)       Date:  2021-02-26       Impact factor: 1.817

7.  Spironolactone Effect in Hepatic Ischemia/Reperfusion Injury in Wistar Rats.

Authors:  Julio César Jiménez Pérez; Araní Casillas Ramírez; Liliana Torres González; Linda Elsa Muñoz Espinosa; Marlene Marisol Perales Quintana; Gabriela Alarcón Galván; Homero Zapata Chavira; Francisco Javier Guzmán de la Garza; Carlos Rodrigo Cámara Lemarroy; Nancy Esthela Fernández Garza; Edelmiro Pérez Rodríguez; Paula Cordero Pérez
Journal:  Oxid Med Cell Longev       Date:  2015-12-21       Impact factor: 6.543

8.  The effect of spironolactone on calcineurin inhibitor induced nephrotoxicity: a multicenter randomized, double-blind, clinical trial (the SPIREN trial).

Authors:  Line Aas Mortensen; Helle C Thiesson; Birgitte Tougaard; Martin Egfjord; Anne Sophie Lind Fischer; Claus Bistrup
Journal:  BMC Nephrol       Date:  2018-05-03       Impact factor: 2.388

9.  EPURE Transplant (Eplerenone in Patients Undergoing Renal Transplant) study: study protocol for a randomized controlled trial.

Authors:  Sophie Girerd; Luc Frimat; Didier Ducloux; Yannick Le Meur; Christophe Mariat; Bruno Moulin; Christiane Mousson; Philippe Rieu; Nassim Dali-Youcef; Ludovic Merckle; Xavier Lepage; Patrick Rossignol; Nicolas Girerd; Frédéric Jaisser
Journal:  Trials       Date:  2018-10-30       Impact factor: 2.279

10.  Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress.

Authors:  Raquel González-Blázquez; Beatriz Somoza; Marta Gil-Ortega; Miriam Martín Ramos; David Ramiro-Cortijo; Elena Vega-Martín; Angela Schulz; Luis Miguel Ruilope; Peter Kolkhof; Reinhold Kreutz; María S Fernández-Alfonso
Journal:  Front Pharmacol       Date:  2018-10-09       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.